Aubrietia Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 27-12-2024
- Paid Up Capital ₹ 1.00 M
as on 27-12-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -50.82%
(FY 2022)
- Profit -669.16%
(FY 2022)
- Ebitda -14.24%
(FY 2022)
- Net Worth -310.59%
(FY 2022)
- Total Assets -48.91%
(FY 2022)
About Aubrietia Pharmaceuticals
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Palanisamy Karthikeyan, Jayalakshmi Palanisamy, and Purushotham Monika serve as directors at the Company.
- CIN/LLPIN
U36994TZ2018PTC030931
- Company No.
030931
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Sep 2018
- Date of AGM
15 Oct 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Salem, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Aubrietia Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jayalakshmi Palanisamy  | Managing Director | 14-Oct-2019 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Palanisamy Karthikeyan | Director | 12-Sep-2018 | Current |
| Purushotham Monika | Director | 03-Oct-2018 | Current |
Financial Performance of Aubrietia Pharmaceuticals.
Aubrietia Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 50.82% decrease. The company also saw a substantial fall in profitability, with a 669.16% decrease in profit. The company's net worth observed a substantial decline by a decrease of 310.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aubrietia Pharmaceuticals?
Unlock access to Aubrietia Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aubrietia Pharmaceuticals?
Unlock and access historical data on people associated with Aubrietia Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aubrietia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aubrietia Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
